reversible SARS-CoV-2 3CLpro inhibitor

Ph. II/III candidate for COVID-19

virtual + HTS MS screen, SBDD


Shionogi Pharmaceutical

reversible SARS-CoV-2 3CLpro inhibitor - Shionogi Pharmaceutical

S-217622 is the first oral, non-covalent, non-peptidic SARS-CoV-2 3CL (main protease) inhibitor clinical candidate, currently in Ph. II/III trials as a once-daily oral treatment for COVID-19. Unlike paxlovid, the…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: